METHOD FOR CARRYING OUT FIBROBRONCHOSCOPIC EXAMINATION

FIELD: medicine. SUBSTANCE: method involves additionally carrying out pulseoxymetric monitoring before administering fibrobronchoscopy. Initial arterial blood saturation with oxygen is measured. The value being below 90- 93%, oxygen inhalation is transnasally administered at a rate of 4-12 l/min dur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DANILIN A.V, SHTEJNER M.L
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	ARTIFICIAL RESPIRATION BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSESOR SPECIFIC PARTS OF THE BODY DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY DIAGNOSIS HUMAN NECESSITIES HYGIENE IDENTIFICATION MASSAGE MEDICAL OR VETERINARY SCIENCE PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING ORSTIMULATING REFLEX POINTS IN THE BODY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SURGERY
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: medicine. SUBSTANCE: method involves additionally carrying out pulseoxymetric monitoring before administering fibrobronchoscopy. Initial arterial blood saturation with oxygen is measured. The value being below 90- 93%, oxygen inhalation is transnasally administered at a rate of 4-12 l/min during 15-40 min before carrying out fibrobronchoscopic examination to achieve arterial blood saturation with oxygen of not lower than 90-93%. beta2-agonist agents are supplied to inhale together with oxygen and then, fibrobronchoscopic examination is carried out under constant rate transnasal oxygen supply conditions and pulse-oxymetric control. Arterial blood saturation with oxygen falling below 80% during fibrobronchoscopic examination, endobronchial oxygen supply is additionally administered via fibrobronchoscope canal. EFFECT: enhanced effectiveness of treatment; prevented bronchospasm arrival and cardiovascular complications occurrence. 3 cl